Non-Small Cell Lung Cancer

A retrospective analysis finds that patients who undergo pneumonectomy or are aged 70 years or older after receiving neoadjuvant concurrent chemoradiation therapy experience less favorable surgical outcomes. Lung cancer, particularly stage IIIA–N2 non-small cell lung cancer (NSCLC), is one of the leading causes of cancer-related deaths worldwide. The most effective treatment approach for this type...

Neoadjuvant chemoimmunotherapy, whether compared to immunotherapy alone or in combination with apatinib, may lead to increased surgical complexity while maintaining an acceptable incidence of postoperative complications, according to the results of a retrospective study. Lung cancer, specifically non-small cell lung cancer (NSCLC), is the leading cause of cancer-related deaths worldwide, accounting for nearly 85% of...

In a retrospective study, patients without a social support network had a shorter survival rate than those with support. Non-small cell lung cancer (NSCLC) continues to be a significant health issue and is a leading cause of death in many countries. Although there are promising new treatments available for certain types of lung cancer, managing...

A cohort study finds that class-switched B cells could potentially be used as a prognostic marker for non-small cell lung cancer and as a target for future therapeutic strategies. Lung cancer is a major global health concern. Significant progress has been made in treatment, with immunotherapy emerging as a recent breakthrough of great promise. The...

The spatial distribution of CD103+CD8+ tissue-resident memory T cells is a prognostic biomarker for non-small cell lung cancer, according to the results of a recent cohort study. Tissue-resident memory T cells (TRM) are a special population of immune cells that reside in solid[spacer height=”10px”]tumors and their microenvironment. Although emerging evidence has linked these cells to[spacer...

Serum levels of 8-hydroxy-deoxyguanosine were positively correlated with ionizing radiation in non-small cell lung cancer, with possible prognostic significance in the squamous pathology subgroup in an observational study. Ionizing radiation is associated with DNA damage, which can be direct or indirect, as with the production of reactive oxygen species (ROS). The most common ROS-induced base...

The long non-coding RNA LINC02159 promotes non-small cell lung cancer progression through ALYREF/YAP1 signaling, according to the results of a recent cell culture study. Lung cancer is the leading cause of cancer-related deaths globally. Long non-coding RNAs (lncRNAs) have recently emerged as key regulators in cancer development and progression, including non-small cell lung cancer (NSCLC),...

Amivantamab plus lazertinib shows durable clinical activity in osimertinib-relapsed, epidermal growth factor receptor-mutated advanced non-small cell lung cancer in a phase I study. Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), is the current standard-of-care treatment for EGFR-mutated non-small cell lung cancer (NSCLC). However, resistance is common, and there are no...

Circulating tumor DNA response to pembrolizumab can identify patients with molecular disease progression needing treatment intensification, according to the results of a phase II/III clinical trial. Circulating tumor DNA (ctDNA) has demonstrated promise in identifying primary resistance to immunotherapy. Concerning non-small cell lung cancer (NSCLC), where pembrolizumab and combination pembrolizumab–carboplatin–taxane/pemetrexed are the first-line options, it...